Kalos Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Kalos Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,167	Closed	-$246K	–	185
2021 Q4	$246K	Buy	3,167 +207	+7%	+$14.3K	0.07%	243
2021 Q3	$230K	Hold	2,960	–	–	0.07%	243
2021 Q2	$261K	Buy	+2,960	New	+$252K	0.11%	215
2021 Q1	–	Sell	-2,530	Closed	-$237K	–	297
2020 Q4	$237K	Buy	+2,530	New	+$202K	0.1%	216

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Kalos Management's ARKG Position: Q1 2022 in Review

Kalos Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 3,167 shares — an estimated $246K sold.

Kalos Management first reported a position in ARKG in Q4 2020 and held it in 4 quarters. The position peaked at $261K in Q2 2021. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

Kalos Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
Kalos Management sold 3,167 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $246K.
Kalos Management first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 4 quarters.
Kalos Management's ARK Genomic Revolution ETF position peaked at $261K in Q2 2021.
387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Kalos Management's 13F filing for Q1 2022, filed 21 Jun 2022.